Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide for AVM Related GI Bleeding
NCT00389935Phase 2Completed
- Sponsor
- Northport VA Medical Center
- Start
- Oct 2006
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in Arteriovenous Malformation (AVM) and hereditary hemorrhagic telangiectasia (HHT), sponsored by Northport VA Medical Center. Primary endpoint: Blood Transfusion requirements at 6 months. Started Oct 2006; status: completed.
02
Drugs
thalidomide
03
Conditions
Arteriovenous Malformation (AVM)hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NCT00389935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00389935.